Century Therapeutics, Inc. (IPSC) News
Filter IPSC News Items
IPSC News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
IPSC News Highlights
- For IPSC, its 30 day story count is now at 6.
- Over the past 4 days, the trend for IPSC's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
- The most mentioned tickers in articles about IPSC are CNTY, ALLO and ASH.
Latest IPSC News From Around the Web
Below are the latest news stories about CENTURY THERAPEUTICS INC that investors may wish to consider to help them evaluate IPSC as an investment opportunity.
Century Therapeutics Presents Initial Data from CNTY-101 Phase 1 ELiPSE-1 Trial Supporting the Potential for a Multi-Dosing Strategy for CAR iNK Enabled by Allo-Evasion™ Edits– Data presented at 65th ASH Annual Meeting show CNTY-101 was generally well tolerated at Dose Level 1 (100 million cells) in a high-risk, heavily pretreated R/R B-cell lymphoma patient – – Preliminary clinical data demonstrate six-month durable complete response in Dose Level 1 in a single patient following multiple cycles of CNTY-101 without lymphodepletion – – Pharmacokinetic data suggests CNTY-101 exposure may be maintained upon administration of additional cycles without lymphodepletion due |
Century (IPSC) Up 36% on FDA Nod to Begin Phase I Lupus StudyCentury (IPSC) set to begin early-stage study on lead product candidate, CNTY-101, for treatment of systemic lupus erythematosus following IND clearance by FDA. The stock rises 36%. |
Century Therapeutics, Inc.'s (NASDAQ:IPSC) largest shareholders are public companies who were rewarded as market cap surged US$47m last weekKey Insights The considerable ownership by public companies in Century Therapeutics indicates that they collectively... |
Century Therapeutics Receives FDA Clearance of IND Application for CNTY-101 in Systemic Lupus Erythematosus– Represents second IND clearance for CNTY-101, the Company’s lead iPSC-derived CD19-targeted CAR NK cell product candidate, and first in an autoimmune and inflammatory disease indication – – Company plans to initiate the Phase 1 clinical trial in the first half of 2024; initial data expected by year-end 2024 – – CNTY-101 is the first cell therapy product candidate engineered with six precision gene edits including a CD19-CAR, Allo-Evasion™ technology, IL-15 cytokine support and a safety switch |
Century Therapeutics to Host Conference Call to Discuss Preliminary Clinical Data from Phase 1 ELiPSE-1 trial of CNTY-101 in Relapsed or Refractory B-cell Lymphomas and Planned Phase 1 Study in Systemic Lupus ErythematosusPHILADELPHIA, Dec. 06, 2023 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology and autoimmune and inflammatory disease, today announced that it will host a conference call and live audio webcast on Monday, December 11 at 7:30 AM PT/ 10:30 AM ET to discuss initial clinical data supporting a multi-dosing strategy from its ongoing first-in-human Phase 1 ELiPSE-1 trial |
Penny Stock Jackpots: 3 High-Stakes Picks With 10-Bagger PotentialThere are penny stocks and then are penny stock picks that are so outrageously wild that they should never be considered unless one is gambling with pocket change. |
Century Therapeutics to Present at the Piper Sandler 35th Annual Healthcare ConferencePHILADELPHIA, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, today announced that members of the management team will participate in a fireside chat at the Piper Sandler 35th Annual Healthcare Conference on Tuesday, November 28, 2023 at 10:00 AM ET. A replay of the event will be available on the “Events & Presentations” page in the “Investors” sec |
FMR LLC Adjusts Position in Century Therapeutics IncOn October 31, 2023, FMR LLC (Trades, Portfolio) made a notable adjustment to its investment portfolio by reducing its stake in Century Therapeutics Inc (NASDAQ:IPSC). FMR LLC (Trades, Portfolio), known widely as Fidelity, is a firm with a rich history dating back to its founding in 1946. |
Century Therapeutics Inc (IPSC) Reports Q3 2023 Financial ResultsFinancial Performance and Strategic Developments in Focus |
Century Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates- Brent Pfeiffenberger, Pharm.D., MBA, appointed Chief Executive Officer of Century Therapeutics - - Initial data from the ongoing Phase 1 ELiPSE-1 trial evaluating CNTY-101 in relapsed or refractory CD19 positive B-cell lymphomas to be presented at the American Society of Hematology (ASH) Annual Meeting - - Announced expanded license agreements with FUJIFILM Cellular Dynamics (FCDI) for the development and commercialization of iPSC-derived cell therapies in autoimmune and inflammatory diseases |